Synovac states that its COVID-19 vaccine is more effective with longer lasting intervals

BEIJING (Reuters) – China’s Synovac Biotech said on Monday that a clinical trial in Brazil showed that its COVID-19 vaccine was about 20 percentage points more effective in the small subset, which took two of its dosages. Used to separate for a long time.

A Synovac spokesperson said the safety rate of 1,394 participants who received a three-week dose of Coronavac or Plesbo was about 70%.

Brazilian researchers announced last week that the total efficacy of the vaccine was 50.4% based on the results of more than 9,000 volunteers, most of whom received doses in addition to the 14 days mentioned in the test protocol.

The spokesperson said that many of the participants received their second shot late for various reasons without any reason.

Gaps for COVID-19 vaccines have become a hot topic of debate among scientists, regulators and governments.

UK regulators have said that a COVID-19 vaccine from AstraZeneca and the University of Oxford is more effective when there is a longer interval between doses than initially envisaged.

The UK has also decided to allow a longer interval between doses of a COVID-19 vaccine from Pfizer and BioNTech, even though the companies say they only have efficacy data for short periods between shots.

A Synovac spokesman warned that the robustness of the data from the subset was weaker than the 50% result, which is based on the combined data from those receiving the dose two or three weeks apart.

While Synovac researchers said early-stage trials indicated a four-week interval stronger than the two-week antibody response, this is the first time the company released efficacy data from a Phase III trial with a dosing pattern Which is different from its test protocol.

Synovac is yet to release the global results of its Phase III trials, but its COVID-19 vaccine has been approved for emergency use in several countries, including Brazil, Indonesia and Turkey.

(Reporting by Roxanne Liu and Ryan Wu. Editing by Mark Potter)

Leave a Reply

Your email address will not be published.